登录 | 注册    微信公众号  
搜索

功能细胞系

背景
细胞水平的分析评价是对在体外进行药物有效性评估的重要指标之一,被广泛地应用在新药研发过程中。但是由于所选用细胞的局限性,很多传统的细胞水平活性分析方法有着灵敏度低,重复性差,操作复杂,检测周期长,通量低等缺点,。比如选用原代细胞的分析方法,由于原代细胞的批间差异大,导致分析方法非常不稳定,因此无法满足新药研发的需求。
通过基因工程方法构建的报告基因细胞株(Reporter cell line)被认为可以克服传统细胞水平分析方法缺点而被逐步广泛运用到新药研发的进程中。报告基因细胞株(Reporter cell line)以药物作用机制(MOA)为基础,在细胞内建立起靶点转导信号与报告基因表达的相关性,通过特定的检测试剂检测报告基因的表达情况以监控靶点信号通路转导,进而构建一种药物靶点特异性的模型细胞株。这类细胞株批间差小,且转入细胞内的检测信号强,以此为基础开发的分析方法灵敏度高,检测周期短,重复性好,并且操作简单。
为满足新药物研发的需求,ACROBiosystems采用荧光素酶报告基因系统建立报告基因细胞平台,持续开发系列高质量报告基因细胞株产品。ACRO开发的系列细胞株产品均通过功能性和稳定性验证,可以应用于信号传导功能研究,早期药物发现,高通量药物筛选选、生物活性测定、稳定性测定、批次放行等方面,为新药研发提供一个稳定且便捷的工具。
产品优势:

基于明确MOA设计,便于药物机制研究;

反应信号强,确保高灵敏度;

检测窗口大, 适用不同药效筛选;

代次稳定性好,利于方法学验证;

应用场景明确,方便客户选择;

配套产品供应,实现一站服务。

应用场景:

细胞内信号转导通路研究;

配体受体之间的相互作用;

早期药物筛选和新药研发;

产品列表
货号 Host cell 产品描述 Applications 订购/预购
CHEK-ATF044 HEK293 VEGFR2 (Luc) HEK293 Reporter Cell Screen for anti-human VEGF or anti-human VEGFR neutralizing antibody

订购

CHEK-ATF045 HEK293 TSLPR (Luc) HEK293 Reporter Cell Screen for anti-human TSLP or anti-human TSLPR neutralizing antibody

订购

CJUR-STF046 Jurkat NFAT (Luc) Jurkat Reporter Cell Screen for T cell activators

订购

CHEK-ATF047 HEK293 STAT3 (Luc) HEK293 Reporter Cell Screen for STAT3 activators or inhibitors

订购

CHEK-ATF048 HEK293 NF-κB (Luc) HEK293 Reporter Cell Screen for NF-kB inhibitors and activators.

订购

CHEK-ATF049 HEK293 EGFR (Luc) HEK293 Reporter Cell Screen for anti-human EGFR or anti-human EGF neutralizing antibody or small molecule inhibitor

订购

CHEK-ATF050 HEK293 NFAT (Luc) HEK293 Reporter Cell Screen NFAT activators or inhibitors

订购

热门产品验证数据&应用案例
TSLPR (Luc) HEK293 Reporter Cell
验证数据
细胞性质验证
Co-expression analysis of human TSLPR and IL7Rα on TSLPR (Luc) HEK293 Reporter Cell by FACS.

Co-expression analysis of human TSLPR and IL7Rα on TSLPR (Luc) HEK293 Reporter Cell by FACS. Cell surface staining was performed on TSLPR (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-TSLPR antibody and FITC-labeled anti-IL7Rα antibody.

Protocol

Response to human TSLP protein (RLU).

Response to human TSLP protein (RLU). The TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (AcroBiosystems, Cat.No.TSP-H52Hb). The EC50 was approximately 0.1392 μg/mL.  

Protocol

Response to human TSLP protein (Fold).

Response to human TSLP protein (Fold). The TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein (AcroBiosystems, Cat.No.TSP-H52Hb). The max induction fold was approximately 45.15.

Protocol

代次稳定性验证
Passage stability analysis of receptors expression by FACS.

Passage stability analysis of receptors expression by FACS. Flow cytometry surface staining of human TSLPR and IL7Rα on TSLPR (Luc) HEK293 Reporter Cell demonstrates consistent mean fluorescent intensity across across passage10-26. (A) Human IL7Rα expression analysis. (B) Human TSLPR expression analysis.

Protocol

Passage stability analysis by Signaling Bioassay.

Passage stability analysis by Signaling Bioassay. The continuously growing TSLPR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TSLP protein. Human TSLP protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-26.

Protocol

应用案例
Inhibition of human TSLP protein-induced reporter activity by anti-human TSLP neutralizing antibody.

Inhibition of human TSLP protein-induced reporter activity by anti-human TSLP neutralizing antibody. This reporter cell was incubated with serial dilutions of antibodies in the presence of human TSLP protein (AcroBiosystems, Cat.No.TSP-H52Hb) with a final concentration of 0.3 μg/mL. The EC50 of anti-human TSLP neutralizing antibody is approximately 0.55 μg/mL.  

Protocol

EGFR (Luc) HEK293 Reporter Cell
验证数据
细胞性质验证
Expression analysis of human EGFR on EGFR (Luc) HEK293 Reporter Cell by FACS.

Expression analysis of human EGFR on EGFR (Luc) HEK293 Reporter Cell by FACS. Cell surface staining was performed on EGFR (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-EGFR antibody.

Protocol

Response to human EGF protein (RLU).

Response to human EGF protein (RLU). The EGFR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3). The EC50 was approximately 56.23 ng/mL.

Protocol

Response to human EGF protein (Fold).

Response to human EGF protein (Fold). The EGFR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3). The max induction fold was approximately 56.

Protocol

代次稳定性验证
Receptor expression Stability。
Passage stability analysis of receptors expression by FACS.

Passage stability analysis of receptor expression by FACS. Flow cytometry surface staining of human EGFR on EGFR (Luc) HEK293 Reporter Cell demonstrates consistent mean fluorescent intensity across across passage10-20.

Protocol

Signaling Bioassay Stability
Passage stability analysis by Signaling Bioassay.

Passage stability analysis by Signaling Bioassay. The continuously growing EGFR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human EGF protein. Human EGF protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-20.

Protocol

应用案例
筛选中和抗体
Inhibition of human EGF protein-induced reporter activity by anti-human EGFR neutralizing antibody.

Inhibition of human EGF protein-induced reporter activity by anti-human EGFR neutralizing antibody. This reporter cell was incubated with serial dilutions of antibodies in the presence of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3) with a final concentration of 50 ng/mL. The EC50 of anti-human EGFR neutralizing antibody (Cetuximab) is approximately 1.793 μg/mL.

Protocol

筛选小分子抑制剂
Inhibition of human EGF protein-induced reporter activity by human EGFR small molecule inhibitor.

Inhibition of human EGF protein-induced reporter activity by human EGFR small molecule inhibitor. This reporter cell was incubated with serial dilutions of inhibitors in the presence of human EGF protein (AcroBiosystems, Cat.No.EGF-H52H3) with a final concentration of 50 ng/mL. The EC50 of human EGFR small molecule inhibitor (Erlotinib) was approximately 0.01 μM.

Protocol

VEGFR2 (Luc) HEK293 Reporter Cell
验证数据
细胞性质验证
Expression analysis of human VEGFR2 on VEGFR2 (Luc) HEK293 Reporter Cell by FACS.

Expression analysis of human VEGFR2 on VEGFR2 (Luc) HEK293 Reporter Cell by FACS. Cell surface staining was performed on VEGFR2 (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-VEGFR2 antibody

Protocol

Response to human VEGF165 protein (RLU).

Response to human VEGF165 protein (RLU). The VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210). The EC50 was approximately 5.13 ng/mL.

Protocol

Inhibition of human VEGF165 protein-induced reporter activity by anti-human VEGF neutralizing antibody.

Response to human VEGF165 protein (Fold). The VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210). The max induction fold was approximately 70.

Protocol

代次稳定性验证
Passage stability analysis of receptor expression by FACS.

Passage stability analysis of receptor expression by FACS. Flow cytometry surface staining of human VEGFR2 on VEGFR2 (Luc) HEK293 Reporter Cell demonstrates consistent mean fluorescent intensity across passage10-32.

Protocol

Passage stability analysis by Signaling Bioassay.

Passage stability analysis by Signaling Bioassay. The continuously growing VEGFR2 (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human VEGF165 protein. Human VEGF165 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 10-32.  

Protocol

应用案例
筛选中和抗体
Inhibition of human VEGF165 protein-induced reporter activity by anti-human VEGF neutralizing antibody.

Inhibition of human VEGF165 protein-induced reporter activity by anti-human VEGF neutralizing antibody. This reporter cell was incubated with serial dilutions of antibodies in the presence of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210) with a final concentration of 10 ng/mL. The EC50 of anti-human VEGF neutralizing antibody (Bavacizumab) is approximately 0.0071 μg/mL. 

Protocol

筛选小分子抑制剂
Inhibition of human VEGF165 protein-induced reporter activity by human VEGFR2 small molecule inhibitor.

Inhibition of human VEGF165 protein-induced reporter activity by human VEGFR2 small molecule inhibitor. This reporter cell was incubated with serial dilutions of inhibitors in the presence of human VEGF165 protein (AcroBiosystems, Cat.NO.VE5-H4210) with a final concentration of 10 ng/mL. The EC50 of human VEGFR2 small molecule inhibitor (Cabozantinib) was approximately 0.0053 μM.  

Protocol

消息提示

请输入您的联系方式,再点击提交!

确定